Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...

Topline data were announced from a phase 3b trial evaluating investigational semaglutide 7.2mg in adults with obesity.

A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R.

Eli Lilly (NYSE: LLY) stock was the picture of health on Friday. Shares of the massive American pharmaceutical company rose ...

Sociodemographic, health care, and clinical factors are associated with receipt of semaglutide in those with obesity but ...

A woman who lost 64 pounds on a compounded form of the weight loss drug semaglutide, marketed as Wegovy and Ozempic, started ...

Maintaining a healthy weight is good for your body and can also help with self-esteem. If you’ve been trying to lose weight, ...

Studied over 36 weeks, in doses from 1.25 mg to 20 mg, patients taking amycretin experienced only "mild to moderate" ...

SUFFOLK COUNTY, N.Y. (PIX11) – Bird Flu has been discovered at a New York duck farm, forcing the business to euthanize the ...

The long-term prospects for the company are evolving with product approvals in China, build-up of consumer healthcare franchise, and a biosimilar pipeline.

Ozempic is synonymous with weight loss for many people. Doctors explain benefits and risks of semaglutide and other GLP-1 ...

The readout comes on the heels of CagriSema’s disappointing Phase III performance, where it missed Novo’s projection of 25% ...